FDA OK for CMS' Atlas-based Autosegmentation
This article was originally published in Clinica
Executive Summary
The US FDA has granted 510(k) clearance for CMS' Atlas-based Autosegmentation (ABAS) software, which produces estimates of anatomy boundary contours to create a radiotherapy treatment plan. The St Louis, Missouri-based company, a subsidiary of Stockholm, Sweden-based Elekta, filed the product in April. The software helps clinicians save time, CMS says, as contouring is usually a time-consuming process. ABAS is also compatible with any radiation treatment planning system that can read standard DICOM RT structure set files, distinguishing it from competing products, the firm added. It has structure-specific algorithms for head and neck and prostate cancer treatments, as well as a general algorithm for other sites.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.